Skip to content

Celyad Oncology

Active
Public limited companyfounded 2007active for 19 yearsRue Emile Francqui 6, 1435 Mont-Saint-Guibert, Belgium35 active companies are registered at this addressKBO/BCE: BE 0891.118.115
Summary

Celyad Oncology has been active since 2007 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €2.2m and a net result of -€564,911. Equity is shrinking by about 46% per year across the filed financial years. Its solvency ranks better than 52% of 239 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).

Overview

Activity
Research and development on biotechnology
NACE 72101
7th largest employer in Walloon Brabant, Research and development sector1 site
Size
€7.3moperating revenue 2025
Staff
10.5 FTE
Equity
€2.2m
Loss
-€564,911
Standalone figures, without subsidiaries
Financial health
86 Excellent Checked score 2025
Bankruptcy probabilitywithin 12 months
0.3%
Structure
Parent
CFIP CLYD LLC · 58.51%
Board
9 members
Holdings
2
  • Hilde Windels BVChair
  • Resilient IDGeneral manager · permanent representative Hannes Iserentant
Auditor: VCBA BDO Bedrijfsrevisoren - Réviseurs d'entreprisesAccounts 51 days early114 of 115 deeds read
Why 86raises riskLoss of €564,911, the second in a row (financial year 2025)1 change of registered office in 24 monthslowers riskLiquidity: current ratio 2.32, cash €1.6mSize: turnover €21,000, 10.5 FTE, total assets €4.0m, files consolidated accountsShow the evidence

Checked score

Score 2025
86 / 100
Excellent
Probability in this band: under 0.55%
Financially better than 48% of its sector peers (NACE 72, small)
Financial strength · tick = 2024
Average
Solvency 81+36
equity 55.5% of total assets
Liquidity 80+12
short-term debt 41.5% · cash 40.5%
Profitability 1+1
return on assets -14.0%
Bankruptcy probability, 12 months
0.3% Very low
0%0.5%1.5%4%10%≥ 25%

About 3 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.1% (165 companies, NACE 72, small)
Last 24 months 11-2024: 0.4% 12-2024: 0.4%● unchanged vs 11-2024 01-2025: 0.4%● unchanged vs 12-2024 02-2025: 0.4%● unchanged vs 01-2025 03-2025: 0.4%● unchanged vs 02-2025 04-2025: 0.5%▲ +0.1 percentage points vs 03-2025 05-2025: 0.4%▼ -0.1 percentage points vs 04-2025 06-2025: 0.5%▲ +0.1 percentage points vs 05-2025 07-2025: 0.5%● unchanged vs 06-2025 08-2025: 0.5%● unchanged vs 07-2025 09-2025: 0.5%● unchanged vs 08-2025 10-2025: 0.3%▼ -0.2 percentage points vs 09-2025 11-2025: 0.5%▲ +0.2 percentage points vs 10-2025 12-2025: 0.5%● unchanged vs 11-2025 01-2026: 0.5%● unchanged vs 12-2025 02-2026: 0.5%● unchanged vs 01-2026 03-2026: 0.5%● unchanged vs 02-2026 04-2026: 0.6%▲ +0.1 percentage points vs 03-2026highest value 05-2026: 0.5%▼ -0.1 percentage points vs 04-2026 06-2026: 0.5%● unchanged vs 05-2026 07-2026: 0.3%▼ -0.2 percentage points vs 06-2026 08-2026: 0.3%● unchanged vs 07-2026 09-2026: 0.3%● unchanged vs 08-2026lowest value 10-2026: 0.3%● unchanged vs 09-2026lowest value
Credit of up to €2,000 on 30-day terms is acceptable
Liquidity ample (current ratio 2.32, compared with 2.92 in 2024, above the usual 1.5; short-term debt: 41.5% and cash: 40.5% of total assets), and 44.5% of the assets are financed with debt and provisions.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 72, small): better than 54% on solvency, 76% on liquidity, 24% on profitability and 38% on growth.

The bankruptcy probability was computed on 20-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum and see how the verdict changes with amount, term and advance.

Signals

Five signals.
lowers riskraises riskneutral
raises risk · Loss of €564,911, the second in a row (financial year 2025)
NBB · annual accounts
lowers risk · Liquidity: current ratio 2.32, cash €1.6m
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
lowers risk · Size: turnover €21,000, 10.5 FTE, total assets €4.0m, files consolidated accounts
Companies of this size fail less often; how much that weighs depends on the rest of its profile.
NBB · annual accounts
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 10-06-2026, 51 days ahead of the deadline.
NBB · 5 filings
Deviation from the deadline
2025
51 days early
2024
71 days early
2023
64 days early
2022
56 days early
2021
68 days early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 5 accounts on average 62 days before the deadline; the sector median (NACE 72) for financial year 2024 is 13 days before the deadline, and 33% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 29 May (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Where today falls in the filing period
21-10-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
Searched since 2021.
KBO publications · our coverage
  1. Capital & shares · Amendment of…Approval · Capital increase ·…
  2. Annual accounts filedfinancial year 2025 · consolidated
  3. Annual accounts filedfinancial year 2025 · full…

Key points

  • Risk: 8 loss-making years in a rowloss financial year 2025 -€564,911 View
  • Caution: Turnover fell in 2025from €185,510 to €21,000 ▼ 88.7% View
  • Board changedlatest change 30-01-2026 · 9 in office 2 joined · 3 left View
  • Positive: 7th largest employer in Walloon Brabant, Research and development sectorin the Checked rankings No. 7 View
  • Positive: Always filed on timeaccounts within the deadline every year 5 years View
  • Known shareholderslargest: CFIP CLYD LLC 58.51% 67.91% View

By topic

Financials

Financial year
2025
Turnover
€21,000
Loss
-€564,911
Solvency
55.5%
Turnover▼ 88.7%
Net result
20182025
Go to Financials

Board & ownership

Board
9 members
Largest shareholder
CFIP CLYD LLC · 58.51%
Known shareholders
67.91%
Auditor
VCBA BDO Bedrijfsrevisoren -…
  • Hilde Windels BVChair
  • Serge GobletDirector
  • Dominic PiscitelliDirector
  • Marina Udier BlagovicDirector
  • Christopher LiPumaDirector

and 4 other directors

Go to Board & ownership

Timeline

Events
147
Since
2007
Next accounts
by 31-07-2027
  1. 08-06-2026Reappointments: VCBA BDO Bedrijfsrevisoren - Réviseurs d'entreprises…
  2. 12-03-2026Resignation: Ami Patel Shah (director)
  3. 30-01-2026Resignation: Matthew Kane (daily management delegate and…
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Research and development on biotechnologyNACE 72101
Founded
24-07-2007
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Articles of association

Provisions read
4
Annual meeting
20 May at 15:00
Purpose
“Le développement de nouvelles technologies médicales et notamment mais non exclusivement…” (deed in French)
Go to Articles of association

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.